Prebet, Thomas <br/><br/>
Mobilization of autologous hematopoietic progenitors and subsequent transplantation is a safe and feasible procedure in chronic phase chronic myelogenous leukemia patients with cytogenetic resistance to imatinib.  [electronic resource] 

 -  Haematologica  Nov 2005 
 - ECR36 p.  digital 
<br/><br/> Publication Type: Case Reports; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1592-8721 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Antimetabolites, Antineoplastic--therapeutic use<br/>Antineoplastic Agents--pharmacology<br/>Benzamides<br/>Combined Modality Therapy<br/>Cytarabine--therapeutic use<br/>Drug Resistance, Neoplasm<br/>Fusion Proteins, bcr-abl--antagonists & inhibitors<br/>Granulocyte Colony-Stimulating Factor--pharmacology<br/>Hematopoietic Stem Cell Mobilization<br/>Humans<br/>Imatinib Mesylate<br/>Interferons--therapeutic use<br/>Lenograstim<br/>Leukemia, Myelogenous, Chronic, BCR-ABL Positive--drug therapy<br/>Leukemia, Myeloid, Chronic-Phase--drug therapy<br/>Male<br/>Peripheral Blood Stem Cell Transplantation<br/>Piperazines--pharmacology<br/>Pyrimidines--pharmacology<br/>Recombinant Proteins--pharmacology<br/>Remission Induction<br/>Transplantation, Autologous